ISRG

At $451.63 the market cap is $159.55B against a $152.87B enterprise value because of $4.04B of net cash (EV/market cap 0.96x). The multiples are 54.61x TTM earnings, 36.33x forward earnings, 13.78x sales, 9.79x book and 34.19x EV/EBITDA. The forward multiple is set on FY2027 consensus EPS of $12.43009 (451.63 / 12.43009 = 36.33x); against FY2026 consensus of $11.25473 that embeds only about 10.4% EPS growth, so a simple P/E-to-growth read is roughly 3.5x rather than the 2.10 PEG reported in the bundle, which must rely on a longer multi-year growth assumption. Either way the stock is expensive on absolute and peer terms: the Zacks coverage in the bundle grades it F on value and cites roughly 34.54x F12M versus a 21x Zacks Medical sector and Stryker's 16.95x, while also noting it sits below the 67.72x five-year median. That 'cheap versus its own history' argument therefore depends on the multiple holding near today's level while growth decelerates, which is a demanding assumption. The $478.30 mean target implies 5.9% upside and the $485.50 median 7.5%, with a $324 low (28.3% below) and a $685 high (51.7% above) — a $361 spread equal to 79.9% of the share price and a clear signal of analyst disagreement about procedure durability and the right multiple for a decelerating grower. Net: a premium franchise at a full multiple where most of the re-rating is already done and the payoff now comes from delivering low-to-mid-teens procedure and EPS growth, not from multiple expansion.

At $451.63 the stock sits 1.08% above the $446.83 EMA200, 6.91% above the $422.43 SMA20 and 10.70% above the $407.996 EMA50 — the first time in the supplied window that price is above all three reference averages simultaneously. The EMA50 is still $38.83, or 8.69%, below the EMA200, so the death-cross alignment from the 2026 downtrend remains intact and no golden cross is close on this data. The October 21 capitulation candle (open $402.50, low $398.99, close $428.12), followed by closes of $443.85 and $452.29, formed a three-day reversal, and October 26 delivered a second consecutive close above the EMA200 with a marginal new local high at $458.81 and a $447.65 low that held the average. Structure is repaired short term and still repairing medium term: at 25.21% below the $603.88 52-week high and only in the 44.7th percentile of the 52-week range, this is a rebound inside a larger correction, not a new uptrend.

Q3 FY2026 EPS of $3.00 beat the $2.64065 consensus by 13.61%, extending the supplied beat streak to seven quarters at a 13.56% average surprise, yet the initial reaction was negative — the stock opened 8.1% lower at $402.50, touched $398.99, closed -2.26% at $428.12 on 4.80 million shares, then reversed to $443.85 and $452.29 on the following two sessions; because the bundle contains no Q3 revenue, margin or guidance detail, the exact cause of that initial selloff (FY2027 procedure commentary, gross-margin/tariff framing, or simple positioning) cannot be verified, and the absolute EPS path ($2.50 to $2.80 to $3.00) is still rising while YoY growth decelerates from +38.1% in Q1 2026 to roughly +16.6% implied for Q4.

The Q3 print and its multi-session reaction remain the dominant item: EPS beat by 13.61%, the stock gapped down 8.1%, closed -2.26% on 2.10x average volume at $428.12, then reversed to $443.85 and $452.29 and has now held the $446.83 EMA200 for two consecutive closes ($451.63, high $458.81). The market is testing whether the EMA200 reclaim is a durable repair or the final retest of a broken long-term trend, with $458.81 the immediate trigger and the $478-$486 target cluster the next reference.

VIX at 18.39 (down 5.45% on the day) sits in the Neutral band and the broad tape rallied, which is supportive, but a 4.986% 10-year Treasury yield still caps multiple expansion for a 36.33x forward P/E name whose $12.43 FY2027 EPS already assumes only about 10.4% growth, so ISRG can grind higher on execution but cannot rely on rate-driven re-rating for upside.

ISRG pairs a durable razor-and-blade franchise (11,710-system da Vinci installed base, roughly 85% recurring revenue, 66.64% gross margin, 38.61% EBITDA margin, $4.04B net cash, zero debt, 17.93% ROE) with a fragile multiple (36.33x forward earnings on FY2027 EPS of $12.43, 34.19x EV/EBITDA, 13.78x sales, 2.15% FCF yield) and beta of 1.463. That combination belongs in a Core Growth sleeve, not a Core Anchor: the cash-flow stream is durable, but procedure growth is decelerating from 17% in Q1 2026 toward a 13.5%-15.5% 2026 guide, tariffs cost roughly one point of gross margin, and 27.77% 20-day realized volatility with a $13.08 ATR (2.90% of price) means routine swings of 3% a day. Expect high-teens to mid-20s peak-to-trough drawdowns, as the 25.21% gap to the $603.88 52-week high already demonstrates, and size it as a deliberate growth holding with a hard, pre-committed stop.